News & Articles

The expanded team will support growth and development, and the commercialization of precision antibiotics to help overcome antimicrobial resistance

Glox Therapeutics, involved in the development of precision antibiotic therapies based on naturally occurring bacteriocins, announced it has secured £1 million in grant funding from PACE (Pathways to Antimicrobial Clinical Efficacy).